

Synthesis of 4-benzoyl-1,2,6-trialkyl-1,2,4,6-tetrazepane-5-thiones by the interaction of 1,2-dialkyldiaziridines with benzoyl isothiocyanate in ionic liquids

Alexander V. Shevtsov,^a Vladimir V. Kuznetsov,^a Konstantin A. Lyssenko,^b Pavel A. Belyakov^a and Nina N. Makhova^{a*}

^a N. D. Zelinsky Institute of Organic Chemistry, Russian Academy of Sciences, 119991 Moscow, Russian Federation.

Fax: +7 495 135 5328; e-mail: mnn@ioc.ac.ru


^b A. N. Nesmeyanov Institute of Organoelement Compounds, Russian Academy of Sciences, 119991 Moscow, Russian Federation.

Fax: +7 495 135 5085; e-mail: kostya@xrlab.ineos.ac.ru

DOI: 10.1070/MC2006v016n04ABEH002380


An interaction of 1,2-dialkyldiaziridines with benzoyl isothiocyanate in the room temperature ionic liquids [emim][BF₄] and [emim][PF₆] unexpectedly resulted in previously unknown 4-benzoyl-1,2,6-trialkyl-1,2,4,6-tetrazepane-5-thiones; the reaction was carried out by the cleavage of the C–N and of the N–N bonds of the diaziridine ring.

The transformation of diaziridine rings under the action of electrophilic reagents is an approach to the synthesis of nitrogen-containing heterocyclic systems.^{1–3} Recently, we have shown that the diaziridine ring was cleaved on the N–N bond in the reaction of 1,2-dialkyldiaziridines with ketenes, resulting in different compounds containing the N–C–N fragment (derivatives of imidazolidin-4-one, β -lactams and 3,5-diacyl-3,5-diazahept-1-enes).^{4–6} At heating, the interaction of 1,2-di-, 1,2,3-tri- and 1,2,3,3-tetraalkyldiaziridines with aroylisocyanates afforded 4-aryol-1,2,4-triazolidin-3-one derivatives by cleavage of the C–N bond followed by cyclization of the formed zwitter-ionic intermediate (Scheme 1).^{7,8}



Scheme 1

In this work, we studied the behaviour of 1,2-dialkyldiaziridines **1a–d** in the reaction with benzoylisothiocyanate **2** with the aim to synthesise 4-benzoyl-1,2,4-triazolidine-3-thiones **3**. The interaction of compounds **1** and **2** was performed both under the conditions used for the preparation of 4-aryol-1,2,4-triazolidin-3-ones (stirring at –20 °C followed by heating in hexane) and in other solvents (chloroform, ethyl acetate and dioxane) at different temperatures (from –30 to 100 °C). However, in all cases the reaction proceeded ambiguously, with the formation of an unseparable mixture of seven to eight compounds (TLC data). Only the use of the room temperature ionic liquids [emim][BF₄] and [emim][PF₆] allowed us to perform this interaction. However, instead of the expected 4-benzoyl-1,2,4-triazolidine-3-thiones **3**, previously unknown 4-benzoyl-1,2,6-trialkyl-1,2,4,6-tetrazepane-5-thiones **4a–d** were isolated as main products (35–51%). Although fused cyclic systems containing seven-membered heterocycles with 1,2,4,6-positions of nitrogen atoms have been described in the literature,^{9,10} monocyclic saturated systems **4** were synthesised for the first time.



Scheme 2 Reagents and conditions: i, PhCONCS **2**, [emim][BF₄] or [emim][PF₆], 20 °C, 24 h.

The assumed reaction mechanism is presented in Scheme 2. The first step of this reaction (in analogy to the interaction of 1,2-dialkyldiaziridines **1** with aroylisocyanates) is likely the formation of 4-benzoyl-1,2,4-triazolidine-3-thiones **3**. However, the reaction does not stop at this step. Evidently, the C=S unit in compounds **3** is strongly polarised due to the influence of the ionic liquids and gains capability to interact with the second

molecule of 1,2-dialkyldiaziridine **1**, resulting in spiro compounds **5**, which then rearrange into 4-benzoyl-1,2,6-trialkyl-1,2,4,6-tetrazepane-5-thiones **4a–d** (Scheme 2). The rearrangement of similar spiro compounds into larger heterocycles is reported in the literature.¹¹ It is interesting to note that the first reaction step is carried out by diaziridine ring opening on the C–N bond, yet the second molecule of diaziridine **1** is built into compound **3** through the N–N bond cleavage.

The structure of the synthesised compounds **4a–d**[†] was established by the overall data of elemental analysis, spectral characteristics and X-ray diffraction studies of compound **4a**.

[†] ¹H and ¹³C NMR spectra were recorded on Bruker AM-300 (300 MHz for ¹H and 75.5 MHz for ¹³C) and Bruker RDX-500 (500 MHz for ¹H and 125 MHz for ¹³C) spectrometers (CDCl₃ was used as an internal standard). Infrared spectra were determined in KBr pellets on a UR-20 spectrometer. Mass spectra were measured on a Finnigan MAT INCOS-50 instrument. TLC was carried out on ALUGRAM SIL G/UV254 plates, ALDRICH. Isolation of new compounds was performed on Kieselgel 60 F₂₅₄ (Merck). Melting points were measured on a Gallenkamp instrument (Sanyo). Ionic liquids [emim][BF₄] and [emim][PF₆] were amiably provided by Merck KGaA. 1,2-Dialkyldiaziridines were synthesised according to the published procedure.¹²

4-Benzoyl-1,2,6-triethyl-1,2,4,6-tetrazepane-5-thione 4a: yield 51%, white solid, mp 122–123 °C, *R*_f 0.33 (eluent, hexane–ethyl acetate, 10:1). ¹H NMR (CDCl₃) δ: 1.07 (t, 3H, Me, ³J 6.87 Hz), 1.14 (t, 3H, Me, ³J 7.33 Hz), 1.27 (t, 3H, Me, ³J 6.87 Hz), 2.66 and 2.71 [2m, 2H, N(1)CH₂Me], 2.79 and 2.86 [2m, 2H, N(2)CH₂Me], 2.44 and 4.16 [2m, 2H, N(6)CH₂Me], 4.32 and 5.58 [2d, 2H, C(3)H₂, ²J –14.21 Hz], 4.39 and 5.53 [2d, 2H, C(7)H₂, ²J –14.21 Hz], 7.35 (t, 2H, Ph, ³J 7.79 Hz), 7.44 (t, 1H, Ph, ³J 7.33 Hz), 7.52 (d, 2H, Ph, ³J 7.33 Hz). ¹³C NMR (CDCl₃) δ: 11.37, 12.47 and 12.85 (Me), 44.68, 45.54 and 49.88 (CH₂Me), 59.46 and 67.70 [CH₂(cycl)], 128.09, 128.16, 131.22 [CH(Ph)], 135.84 [C(Ph)], 171.31 (CO), 189.13 (CS). IR (ν/cm^{–1}): 632, 668, 692, 732, 780, 792, 824, 1016, 1076, 1092, 1104, 1128, 1144, 1200, 1224, 1252, 1280, 1304, 1336, 1352, 1376, 1428, 1496, 1580, 1664, 2840, 2924, 2964, 3056. MS, *m/z*: 321 (M⁺ + 1).

4-Benzoyl-1,2,6-tripropyl-1,2,4,6-tetrazepane-5-thione 4b: yield 35%, white solid, mp 67–69 °C, *R*_f 0.48 (eluent, hexane–ethyl acetate, 10:1). ¹H NMR (CDCl₃) δ: 0.87 (t, 3H, Me, ³J 6.87 Hz), 0.94 (t, 6H, 2Me, ³J 7.33 Hz), 1.50–1.65 [m, 4H, N(1)CH₂CH₂Me and N(2)CH₂CH₂Me], 1.72 and 1.79 [2m, 2H, N(3)CH₂CH₂Me], 2.54 and 2.63 [2m, 2H, N(1)CH₂CH₂], 2.72 and 2.81 [2m, 2H, N(2)CH₂CH₂], 3.24 and 4.12 [2m, 2H, N(6)CH₂CH₂], 4.28 and 5.51 [2d, 2H, C(3)H₂, ²J –14.21 Hz], 4.33 and 5.62 [2d, 2H, C(7)H₂, ²J –14.21 Hz], 7.36 (t, 2H, Ph, ³J 7.33 Hz), 7.44 (t, 1H, Ph, ³J 7.33 Hz), 7.52 (d, 2H, Ph, ³J 7.33 Hz). ¹³C NMR (CDCl₃) δ: 11.25 and 11.73 (Me), 19.68, 20.25 and 20.47 (CH₂Me), 52.47, 53.41 and 56.88 (NCH₂CH₂), 59.19 and 68.36 [CH₂(cycl)], 128.06, 128.10, 131.19 [CH(Ph)], 135.87 [C(Ph)], 171.30 (CO), 189.23 (CS). IR (ν/cm^{–1}): 636, 692, 740, 796, 944, 1016, 1080, 1104, 1144, 1192, 1220, 1236, 1264, 1292, 1304, 1328, 1348, 1384, 1420, 1448, 1488, 1584, 1604, 1672, 2872, 2932, 2960, 3060. MS, *m/z*: 362 (M⁺).

4-Benzoyl-1,2,6-tributyl-1,2,4,6-tetrazepane-5-thione 4c: yield 43%, white solid, mp 75–76 °C, *R*_f 0.56 (eluent, hexane–ethyl acetate, 10:1). ¹H NMR (CDCl₃) δ: 0.88 (t, 3H, Me, ³J 7.33 Hz), 0.95 (t, 6H, 2Me, ³J 7.33 Hz), 1.38–1.46 (m, 6H, 3CH₂CH₂Me), 1.47–1.60 [m, 4H, N(1)CH₂CH₂Me and N(2)CH₂CH₂Me], 1.68 and 1.76 [2m, 2H, N(3)CH₂CH₂Me], 2.59 and 2.68 [2m, 2H, N(1)CH₂CH₂], 2.74 and 2.83 [2m, 2H, N(2)CH₂CH₂], 3.25 and 4.14 [2m, 2H, N(6)CH₂CH₂], 4.25 and 5.51 [2d, 2H, C(3)H₂, ²J –14.20 Hz], 5.30 and 5.62 [2d, 2H, C(7)H₂, ²J –14.21 Hz], 7.36 (t, 2H, Ph, ³J 7.33 Hz), 7.53 (t, 1H, Ph, ³J 7.33 Hz), 7.52 (d, 2H, ³J 7.33 Hz). ¹³C NMR (CDCl₃) δ: 13.71, 13.91 and 13.95 (Me), 20.18, 20.28 and 20.36 (CH₂Me), 28.34, 29.15 and 29.35 (NCH₂CH₂), 50.31, 51.22 and 55.16 (NCH₂CH₂), 59.12 and 68.23 [CH₂(cycl)], 128.05, 128.12, 131.19 [CH(Ph)], 135.90 [C(Ph)], 171.28 (CO), 189.16 (CS). IR (ν/cm^{–1}): 644, 692, 752, 796, 824, 920, 948, 1020, 1028, 1088, 1100, 1152, 1180, 1212, 1224, 1248, 1264, 1292, 1336, 1352, 1368, 1424, 1484, 1560, 1584, 1600, 1668, 2860, 2872, 2932, 2956. MS, *m/z*: 405 (M⁺ + 1).

4-Benzoyl-1,2,6-tris(2-phenylethyl)-1,2,4,6-tetrazepane-5-thione 4d: yield 31%, white solid, mp 85–87 °C, *R*_f 0.36 (eluent, hexane–ethyl acetate, 10:1). ¹H NMR (CDCl₃) δ: 2.63–2.97 [m, 10H, CH₂Ph, N(1)CH₂CH₂Ph and N(2)CH₂CH₂Ph], 3.02 and 3.94 [2m, 2H, N(6)CH₂CH₂], 3.96 and 5.37 [2d, 2H, C(3)H₂, ²J –14.21 Hz], 4.37 and 5.66 [2d, 2H, C(7)H₂, ²J –14.21 Hz], 7.12–7.58 (m, 20H, 4Ph). ¹³C NMR (CDCl₃) δ: 33.61, 33.85 and 34.26 (CH₂Ph), 52.19, 53.11 and 57.32 (NCH₂CH₂), 58.99 and 69.06 [CH₂(cycl)], 125.99, 126.19, 126.66, 126.84, 127.33, 128.10, 128.23, 128.38, 128.64, 128.67, 128.73, 129.00, 131.34, 131.68, 133.40, 135.75, 138.09, 138.18, 139.59, 139.64 (Ph), 171.45 (CO), 189.38 (CS). MS, *m/z*: 549 (M⁺ + 1).




Figure 1 The general view of **4a** in the representation of atoms by thermal ellipsoids (*p* = 50%). Selected bond lengths (Å): S(1)–C(5) 1.656(1), N(1)–N(2) 1.437(1), N(1)–C(7) 1.437(2), N(1)–C(8) 1.461(2), N(2)–C(3) 1.442(2), N(2)–C(10) 1.470(2), C(3)–N(4) 1.485(2), N(4)–C(5) 1.420(2), N(4)–C(12) 1.396(2), C(5)–N(6) 1.340(2), N(6)–C(19) 1.477(2), N(6)–C(7) 1.493(2); bond angles (°): C(7)–N(1)–N(2) 115.7(1), C(7)–N(1)–C(8) 114.5(1), N(2)–N(1)–C(8) 111.3(1), C(3)–N(2)–N(1) 113.3(1), C(3)–N(2)–C(10) 114.6(1), N(1)–N(2)–C(10) 110.0(1), N(2)–C(3)–N(4) 115.4(1), C(12)–N(4)–C(5) 123.5(1), C(12)–N(4)–C(3) 119.1(1), C(5)–N(4)–C(3) 115.2(1), N(6)–C(5)–N(4) 111.5(1), N(6)–C(5)–S(1) 126.3(1), N(4)–C(5)–S(1) 121.9(1), C(5)–N(6)–C(19) 121.1(1), C(5)–N(6)–C(7) 120.7(1), C(19)–N(6)–C(7) 117.1(1).

According to X-ray diffraction analysis,[‡] in **4a** the 1,2,4,6-tetrazepane-3-thione ring is characterised by a distorted chair conformation: the chair base is formed by C(3), N(4), C(7) and N(1) atoms (Figure 1). The N(1) and N(2) atoms are pyramidal [the bond angles are 341.5(1) and 337.9(2)°]. The ethyl groups at N(1) and N(2) are characterised by *trans*-disposition in respect to the chair base with the torsion angle C(8)N(1)N(2)C(10) equal to 144.7°.

Alternatively the atoms N(4) and N(6) are characterised by a flattened pyramidal configuration, the bond angles being 357.9(1) and 358.9(1)°. The flattening of the atoms N(4) and N(6) clearly is a consequence of the conjugation with the C=O and the C=S groups, respectively, which is clearly reflected in the shortening of the corresponding N–C bonds. The dihedral angle between N(4)C(12)O(1) and N(4)C(5)N(6)S(1) planes is 24.7°.

Thus, the interaction of 1,2-dialkyldiaziridines **1** with benzoyl-isothiocyanate **2** was successful only in room temperature ionic liquids and the reaction products unexpectedly appeared to be previously unknown 4-benzoyl-1,2,6-trialkyl-1,2,4,6-tetrazepane-5-thiones **4a–d**.

Note that synthesised compounds **4a–d** have a rather high configuration stability. According to the ¹H NMR data the geminal protons at C(3) and C(7) carbon atoms exhibit as AB systems: coalescence does not occur till 80 °C (reflux in benzene).

This work was supported by the Russian Foundation for Basic Research (grant no. 04-03-32799) and Merck KGaA.

[‡] Crystallographic data for **4a**: C₁₆H₂₄N₄OS, *M* = 320.45, monoclinic, space group *P*2₁/*c*, at 110 K: *a* = 8.3152(8) Å, *b* = 11.0009(11) Å and *c* = 9.145(2) Å, β = 93.538(5)°, *V* = 1720.3(3) Å³, *Z* = 4 (*Z'* = 1), *d*_{calc} = 1.237 g cm^{–3}, μ(MoKα) = 1.96 cm^{–1}, *F*(000) = 688. Intensities of 15426 reflections were measured with a Smart 1000 CCD diffractometer [λ(MoKα) = 0.71072 Å, ω-scans, 2θ < 60°] and 5003 independent reflections (*R*_{int} = 0.0545) were used in a further refinement. The structure was solved by a direct method and refined by the full-matrix least-squares technique against *F*² in the anisotropic-isotropic approximation. Hydrogen atoms were located from the Fourier synthesis and refined in the isotropic approximation. The refinement converged to *wR*₂ = 0.0805 and *GOF* = 0.987 for all independent reflections [*R*₁ = 0.0422 was calculated against *F* for 2930 observed reflections with *I* > 2σ(*I*)]. All calculations were performed using the SHELXTL PLUS 5.0.

Atomic coordinates, bond lengths, bond angles and thermal parameters have been deposited at the Cambridge Crystallographic Data Centre (CCDC). These data can be obtained free of charge via www.ccdc.cam.ac.uk/conts/retrieving.html (or from the CCDC, 12 Union Road, Cambridge CB2 1EZ, UK; fax: +44 1223 336 033; or deposit@ccdc.cam.ac.uk). Any request to the CCDC for data should quote the full literature citation and CCDC reference number 616741. For details, see 'Notice to Authors', *Mendeleev Commun.*, Issue 1, 2006.

References

- 1 (a) E. Schmitz, *Adv. Heterocycl. Chem.*, 1979, **24**, 63; (b) E. Schmitz, in *Comprehensive Heterocyclic Chemistry*, ed. W. Lwowski, Pergamon Press, Oxford, 1984, vol. 1, p. 195.
- 2 H. W. Heine, in *Diaziridines, 3H-Diazirines, Diaziridinones and Diaziridinimines, Small Ring Heterocycles*, ed. A. Hassner, Wiley-Interscience, New York, 1983, part 2, ch. IV, pp. 547–629.
- 3 R. G. Kostyanovsky, R. Murugan and M. Sutharchanadevi, in *Comprehensive Heterocyclic Chemistry*, 2nd Int. edn., eds. A. R. Katritzky and C. W. Rees, Pergamon Press, Oxford, 1996, ch. 1.11, pp. 347–364.
- 4 A. V. Shevtsov, V. Yu. Petukhova, Yu. A. Strelenko, K. A. Lyssenko, I. V. Fedyanin and N. N. Makhova, *Mendeleev Commun.*, 2003, 221.
- 5 A. V. Shevtsov, V. Yu. Petukhova, Yu. A. Strelenko and N. N. Makhova, *Mendeleev Commun.*, 2005, 29.
- 6 A. V. Shevtsov, V. Yu. Petukhova, Yu. A. Strelenko, K. A. Lyssenko, N. N. Makhova and V. A. Tartakovsky, *Izv. Akad. Nauk, Ser. Khim.*, 2005, 997 (*Russ. Chem. Bull., Int. Ed.*, 2005, **54**, 1021).
- 7 M. Komatsu, N. Nishikaze, M. Sakamoto, Y. Ohshiro and T. Agawa, *J. Org. Chem.*, 1974, **39**, 3198.
- 8 A. V. Shevtsov, V. V. Kuznetsov, S. I. Molotov, K. A. Lyssenko and N. N. Makhova, *Izv. Akad. Nauk, Ser. Khim.*, 2006, 534 (*Russ. Chem. Bull., Int. Ed.*, 2006, **55**, 554).
- 9 J. Barkoczy and J. Reiter, *J. Heterocycl. Chem.*, 1993, **30**, 1009.
- 10 J. Lagona, J. C. Fettingier and L. Isaacs, *J. Org. Chem.*, 2005, **25**, 10381.
- 11 T. Tsuchiya, M. Yasumoto and I. Shibuya, *Chem. Lett.*, 1989, 1357.
- 12 N. N. Makhova, A. N. Mikhailyuk, V. V. Kuznetsov, S. A. Kutepov and P. A. Belyakov, *Mendeleev Commun.*, 2000, 182.

Received: 2nd May 2006; Com. 06/2725